CREBBP and prostate carcinoma: A-485 and the CBP/p300 bromodomain inhibitors CBP30, GNE-049 and CCS1477 reduce histone acetylation, suppress androgen receptor target gene transcription, and induce considerable anticancer effects against castration-resistant prostate cancer in mouse models 67, 72, 90, 97 (Tables 2 and 3).